2 completed, 2 recruiting, 2 withdrawn, 1 terminated. 5 Phase 1, 3 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 2, Completed 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
Follow C188-9 compound: new trials by email Literature Review of C188-9 compound trials Research Report on C188-9 compound
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) TTI-101, Pembrolizumab - Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-09-23 | 2025-12-17 | |
| Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck Control Group, TTI-101 - Squamous Cell Carcinoma of Head and Neck | Early Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2025-06-20 | 2025-12-08 | |
| Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma TTI-101, Stereotactic body radiation therapy - Pancreatic Cancer | Phase 1 | Recruiting | Washington University School of Medicine | 24 | 2024-01-16 | 2026-11-06 |
| Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis TTI-101, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Tvardi Therapeutics, Incorporated | 100 | 2023-05-15 | 2026-08-13 |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma TTI-101, Pembrolizumab, Atezolizumab - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | Tvardi Therapeutics, Incorporated | 193 | 2023-03-23 | 2026-10-22 |
| Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer TTI-101, Palbociclib, Aromatase inhibitor (AI) - Breast Cancer | Phase 1 | Terminated | Tvardi Therapeutics, Incorporated | 6 | 2023-01-09 | 2026-09-24 |
| Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers TTI-101 - Breast Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Completed | Tvardi Therapeutics, Incorporated | 64 | 2017-11-15 | 2025-03-21 |
Squamous Cell Carcinoma of Head and Neck (3) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Idiopathic Pulmonary Fibrosis (1) · Liver Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Tvardi Therapeutics, Incorporated (4) · M.D. Anderson Cancer Center (2) · Washington University School of Medicine (1)
United States (5)
Andrew Sikora, MD,PHD (1) · Apostolia Tsimberidou, MD, PhD (1) · Faye Johnson, MD (1) · Sana Karam, M.D., Ph.D. (1)
R01CA255960 (1)